- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02204826
Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study
Korean Red ginseng (KRG) has long been applied to various diseases as a health-promoting herbal medicine in Korea. Many clinical studies of ginseng have been performed to elucidate its therapeutic characteristics. KRG has been shown to be effective in many diseases, such as cancers, hypertension, Alzheimer's disease, diabetes, acquired immune deficiency syndrome, and sexual dysfunction. Several studies have indicated effects of ginseng on improving spermatogenesis in animals. The major mechanisms behind these effects were speculated to be anti-oxidant and anti-aging effects, as well as modulation of the hypothalamus-pituitary-testis axis [7 - 10]. However, there have been no controlled human clinical trials to evaluate the effects of KRG on spermatogenesis in patients with male infertility.
Only a small proportion of causes of male infertility are currently curable, including male hypogonadal disorders that can be cured by gonadotropic agents, and obstructive azoospermia that can be corrected by surgery. In addition, evidence-based medicine has revealed that most empirical treatments are ineffective. Similarly, the efficacies of carnitine, anti-estrogens, kallikrein, vitamins C and E, and glutathione have not been confirmed.
Therefore, the investigators investigated the effects of KRG on semen parameters in male infertility patients. This is the first placebo-controlled trial to evaluate the therapeutic effects of KRG in male patients.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Busan, Korea, Republic of, 602-739
- Department of Urology, Pusan National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients should be males, 25 - 45 years of age, who had complained of infertility for at least 12 months, and had no history of surgical or medical treatments for infertility.
- Increased retrograde flow in the internal spermatic vein with venous diameter > 3 mm during the Valsalva maneuver on scrotal ultrasonography was used as an indicator of varicocele [13].
Varicocele was graded according to the criteria presented by Lyon et al. [14]: *Grade I, palpable only with the Valsalva maneuver
- Grade II, palpable without the Valsalva maneuver
- Grade III, visible from a distance.
Exclusion Criteria:
- A history of vasectomy or obstructive azoospermia
- Chromosomal abnormalities
- Hypogonadism or pituitary abnormalities
- Anatomical abnormality of the genitals
- Significant hepatopathy (liver enzymes elevated 2 - 3-fold higher than the normal range)
- Renal insufficiency (serum creatinine level > 2.5 mg/dL)
- Medical treatment for infertility during the past 4 weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: V + KRG group (n = 20)
three capsules of KRG (500 mg/dose) daily and varicocelectomy.
|
The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C. KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks.
Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
|
Active Comparator: non-V + KRG group
three capsules of KRG (500 mg/dose) daily
|
The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C. KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks. |
Active Comparator: V + P group (n = 20)
placebo capsules and varicocelectomy
|
Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
|
Placebo Comparator: non-V + P group
non-V + P group (n = 20) placebo capsules
|
The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C. KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Semen parmaters change from baseline to post-treatment
Time Frame: Before treatment, After 14 weeks (12 week treatment and 2 week wash out periond)
|
1) sperm concentration, 2) percent motility, 3) sperm viability, and 4) Kruger/strict morphology using World Health Organization (WHO) methodologies (4th edition).
|
Before treatment, After 14 weeks (12 week treatment and 2 week wash out periond)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in hormonal parameters after treatment
Time Frame: Before treatment, After 14 weeks (12 week treatment and 2 week wash out periond)
|
Serum concentrations of FSH and LH were measured using chemiluminescence assays, and serum total testosterone was quantified by radioimmunoassay.
The hormonal status of all patients was recorded at the initial screening visit and post-treatment.
|
Before treatment, After 14 weeks (12 week treatment and 2 week wash out periond)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hyun Jun Park, PhD, MD, Department of Urology, Pusan National University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KRG-infertility
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Male Infertility
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Reproductive Medicine Associates of New JerseyTerminated
-
Jinling Hospital, ChinaRecruitingMale Infertility Due to HypospermatogenesisChina
-
Sapientiae InstituteTerminated
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
Hillel Yaffe Medical CenterUnknownMale Infertility With Severe Oligo-terato-asteno-spermiaIsrael
-
Assiut UniversityNot yet recruitingMale Infertility Due to Azoospermia
-
Universitair Ziekenhuis BrusselRecruitingMale InfertilityBelgium
Clinical Trials on Korean Red Ginseng (KRG)
-
Hanyang UniversityThe Korean Society of GinsengUnknownRheumatic Diseases | Sjögren's Syndrome | Korean Red GinsengKorea, Republic of
-
Daegu Catholic University Medical CenterThe Korean Society of GinsengCompletedHypertensionKorea, Republic of
-
Unity Health TorontoHeart and Stroke Foundation of CanadaCompletedHypertension | Blood Pressure | Endothelial FunctionCanada
-
Chuncheon Sacred Heart HospitalCompleted
-
The Korean Society of GinsengCompleted
-
The Korean Society of GinsengCompleted
-
Shanghai Jiao Tong University School of MedicineRenJi Hospital; Beijing Obstetrics and Gynecology Hospital; Foshan Fuxing Changcheng... and other collaboratorsRecruitingAntioxidative Stress | Healthy AgeingChina
-
Korea Ginseng CorporationNutrasource Pharmaceutical and Nutraceutical Services, Inc.RecruitingCardiovascular Diseases | Platelet Aggregation | Vasodilation | Blood Pressure DisordersUnited States
-
Unity Health TorontoCompletedMetabolic Syndrome | Type 2 DiabetesCanada
-
Korea UniversityThe Korean Society of GinsengCompletedMajor Depressive DisorderKorea, Republic of